Pear Therapeutics is developing the Pear-010 digital therapeutic for virtual reality-delivered pain reduction in adults with acute postoperative and postprocedural pain. Its inclusion in FDA’s Safer Technologies Program (STeP) program suggests the FDA is committed to continuing that program for products that treat non-life-threatening or reversible conditions.

Pear Therapeutics signed an agreement with SoftBank to develop a Japan-focused digital therapeutic, but regulatory questions remain.

Big Health will use its $75m in new funding to scale the business, with plans to launch six new digital therapeutics by 2024. Former US FDA official Anand Shah will join its board of directors.

Medtech Insight spoke to Pear Therapeutics CEO Corey McMann about the emerging digital therapeutics market and his company’s future now that it has the first PDT covered by Medicaid.